To further explore the mechanism by which TY ameliorates RA, we verified the core targets predicted by network pharmacology, including PI3K, AKT1, TNF‐α, IL‐1β, IL‐6, MMPs, and TIMP1. This evidence concerns the gene TIMP1 and rheumatoid arthritis.